Letter to the Editor: Pre-Existing Neuropathy Favours SARS-CoV-2 Vaccination Associated Guillain-Barre Syndrome

Abstract

We read with interest the article by Kim et al.1 about two patients with SARS-CoV-2 vaccination associated Guillain Bare syndrome (GBS) (SC2VG). Patient-1 was a 42-year-old male who developed bilateral facial palsy, dysphagia, quadriparesis, and respiratory insufficiency requiring intubation and mechanical ventilation 2 weeks after the first dose of the AstraZeneca vaccine (AZV).1 Upon cerebrospinal fluid (CSF) investigations and nerve conductions studies (NCSs) the patient was diagnosed with GBS received intravenous immunoglobulins, with a beneficial effect.1 Patient-2 was a 48-year-old female with a history of diabetes and arterial hypertension who developed left facial palsy, dysarthria, severe myalgia, numbness, and muscle weakness two weeks after the first dose of the Biontech Pfizer vaccine (BPV).1 SC2VG was suspected and confirmed by CSF and NCSs. 1 IVIG were given with a significant beneficial effect.1 The study is appealing but raises concerns that need to be discussed